(PDF) Safety, Efficacy, and Biomarker Exploration in a

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma

Clinical Ovarian Cancer

doi 10.1016/j.cloc.2011.04.003

Full Text

Open PDF

Abstract

Available in full text

Date

June 1, 2011

Authors

Publisher

Elsevier BV

Related search

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

British Journal of Cancer

Cancer Research

Oncology

2006

English

Efficacy and Safety of Oxaliplatin, Bevacizumab and Oral S-1 for Advanced Recurrent Colorectal Cancer

Molecular and Clinical Oncology

Cancer Research

Oncology

2016

English

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

Journal of Clinical Oncology

English

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

PLoS ONE

Multidisciplinary

2012

English

Bevacizumab Combined With Gemcitabine and Capecitabine for Advanced Pancreatic Cancer: A Phase II Study

British Journal of Cancer

Cancer Research

Oncology

2009

English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer

Cancer Research

Oncology

2009

English

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research

English

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

Clinical Colorectal Cancer

Oncology

Gastroenterology

2011

English

A Multi-Center Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Cancer Chemotherapy and Pharmacology

English

Amanote Research

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma

Clinical Ovarian Cancer

doi 10.1016/j.cloc.2011.04.003

Full Text

Abstract

Date

Authors

Publisher

Related search

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

Efficacy and Safety of Oxaliplatin, Bevacizumab and Oral S-1 for Advanced Recurrent Colorectal Cancer

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

Bevacizumab Combined With Gemcitabine and Capecitabine for Advanced Pancreatic Cancer: A Phase II Study

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

A Multi-Center Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma